Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04319705
Other study ID # 0052256
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 2, 2020
Est. completion date December 31, 2022

Study information

Verified date July 2021
Source Bispebjerg Hospital
Contact Muzhda Ghanizada, MD
Phone +45 29 20 48 43
Email muzhdaghanizada@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the anti-viral effects of low-dose AZM treatment in patients with asthma and COPD with an exacerbation history. The investigators expect that long-term treatment with low dose AZM modulates the immune response to viral infections, with an increased interferon release, in patients with asthma and COPD with an exacerbation history. In addition, the investigators expect a decrease in inflammatory cells and mediators, and changes in bacteria, measured in samples from the lungs. Half of the participants will receive azithromycin on top of their regular asthma/COPD treatment, while the other half will receive placebo on top of their regular asthma/COPD treatment.


Description:

Asthma and COPD are responsible for considerable global morbidity and healthcare costs, primarily driven by exacerbations, i.e. acute flare-ups. Hence there is a clear need for better interventions preventing exacerbations. A majority of exacerbations are driven by infections, and in particular viral infections. Importantly, the anti-viral defense in asthma and COPD seems compromised, with a relative inability to combat infections, but also a disproportionate inflammatory response to infections, i.e. an increased immunoreactivity involving release of epithelial 'alarmins', such as IL-33 and thymic stromal lymphopoietin (TSLP). Long-term low dose macrolides have been shown to reduce exacerbations in both diseases and are increasingly used clinically, but the mechanism of action is unknown. Macrolides have anti-viral properties in vitro, however their anti-viral properties have not been established in patients with asthma and COPD during exacerbations. The purpose of this study is to investigate the anti-viral and anti-inflammatory effects in the airways, as well as the effects of azithromycin on the lung microbiome. In order to study these effects, the key endpoints in this trial will need to be obtained from bronchoscopic sampling of bronchial brushes, bronchial biopsies and BAL. But performing bronchoscopies during acute exacerbations, when patients are infected with respiratory viruses, is difficult in view of safety. Therefore, this study on in vitro rhinovirus responses of human bronchial epithelial cells before and after in vivo treatment with macrolides represents a novel model to study treatment effects on immunoreactivity during exacerbations. The investigators hypothesize that long-term treatment with low dose AZM modulates the immune response to viral infections, with an increased interferon release, in patients with asthma and COPD with an exacerbation history. The investigators also speculate that AZM treatment leads to a decreased release of the epithelial alarmins (e.g. IL-33 and TSLP) in response to viral infection, in patients with asthma and COPD with an exacerbation history. Furthermore, treatment effects of low dose AZM on functional and compositional changes of bacterial communities of the respiratory- and gastrointestinal tract, and their association with changes in immunoreactivity will be studied. This trial offers the opportunity to study potential biomarkers and surrogate endpoints, but also to identify the anti-inflammatory effects of azithromycin on a mechanistic level. This study is a randomized, double-blind, placebo-controlled trial. It includes a enrolment period of maximum 4 weeks, with a bronchoscopy before and after 12 weeks of treatment (500mg azithromycin or placebo, 3 times per week).


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 31, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Asthma patients (n=40) 1. Diagnosis of asthma according to GINA, with confirmed variable airflow obstruction at screening visit or previously. 2. Age = 18 through 75 years. 3. A postbronchodilator FEV1 = 50% predicted 4. Maintenance treatment with ICS and = 1 second controller (LABA, LAMA, LTRA or Xanthines) for at least three months prior to Visit 1. 5. Non-smokers (<10 packyears, quit >6 months). 6. = 1 Systemic steroid treated exacerbation in the past one year despite maintenance treatment with inhaled corticosteroids. 7. Eosinophilic (n=20, blood eosinophils = 0.200x109/L) and non-eosinophilic (n=20, blood eosinophils <0.200x109/L) phenotypes. - COPD patients (n=40) 1. Diagnosis of COPD according to GOLD 2. Age = 45 through 75 years. 3. = 10 packyears smoking history (current or ex-smokers). 4. A postbronchodilator FEV1 = 30% predicted. 5. Maintenance treatment with long-acting bronchodilators (LABA and/or LAMA) = ICS. 6. = 1 Systemic steroid and/or antibiotic treated exacerbation in the past one year. 7. Eosinophilic (n=20, blood eosinophils =0.200x109/L) and non-eosinophilic (n=20, blood eosinophils <0.200x109/L) phenotypes. - Healthy controls (n=20) 1. Asymptomatic 2. Non-smoking (<10 packyears, quit >6 months) 3. Normal spirometry (FEV1, FVC, FEV1/FVC ratio: all >LLN) 4. FeNO < 25 ppb 5. Non-atopic based on skin-prick test 6. Negative mannitol provocation test 7. Younger (n=10, 18-45 years) and older (n=10, >45-75 years) subjects. Exclusion Criteria: - Any of the following would exclude the subject from participation in the study: 1. Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (e.g., hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible. 2. Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, moderate-severe bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome, active tuberculosis). In addition for the different groups the following: 1. Patient with asthma: concomitant COPD. 2. Patients with COPD: concomitant asthma (former and current) 3. Healthy subjects: COPD and asthma. 3. Any clinically relevant abnormal findings in hematology or clinical chemistry (laboratory results from Visit 1), physical examination, vital signs during the screening, which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study. 4. Evidence of active liver disease, including jaundice or aspartate transaminase, alanine transaminase, or alkaline phosphatase >1.5 times the upper limit of normal (laboratory results from Visit 1). 5. GFR <30 ml/min. 6. Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 2 weeks prior to Visit 1, during the run-in period, or at Visit 2 (randomization). 7. A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report. 8. History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation. 9. History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency. 10. Receipt of any of the following within 30 days prior to Visit 1: 1. Immunoglobulin or blood products, or 2. Receipt of any investigational non-biologic agent within 30 days or 5 half-lives prior Visit 1, whichever is longer. 11. Pregnant, breastfeeding or lactating females 12. History of chronic alcohol or drug abuse within 12 months prior to Visit 1. 13. Planned surgical procedures requiring general anesthesia or in-patient status for > 1 day during the conduct of the study. 14. Unwillingness or inability to follow the procedures outlined in the protocol. 15. Concurrent enrollment in another clinical study involving an investigational treatment. 16. Receipt of any live or attenuated vaccines within 15 days prior to Visit 1. 17. Long QTc interval on ECG (QTc >480msec). 18. History of the following cardiac comorbidities: 1. Life-threatening arrhythmias 2. Myocardial infarction (NSTEMI or STEMI) less than 6 months before start of the study 3. Unstable angina 4. History of severe heart failure 19. Documented severe hypokalemia (K <3.0 mmol/L) or hypomagnesemia (Mg <0.5 mmol/L). 20. Life expectancy <6 months. 21. Hearing impairment. 22. Oxygen saturation <92% at room air, patients on LTOT, history of chronic respiratory failure (hypercapnia).

Study Design


Intervention

Drug:
Azithromycin
Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
Placebo oral tablet
capsule containing placebo, 3 times per week, 12-week treatment period, administered orally

Locations

Country Name City State
Denmark University Hospital Bispebjerg and Frederiksberg Copenhagen

Sponsors (4)

Lead Sponsor Collaborator
Bispebjerg Hospital Herlev and Gentofte Hospital, Lund University, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary IFN-beta gene and/or protein expression To investigate the potential change in viral induced interferon response in HBECs from baseline and after 12 weeks of treatment with low dose azithromycin or placebo, after stimulation with viral infection mimics (RV16 or Poly (I:C) 12 weeks
Primary Viral load To investigate the potential change in viral load response in HBECs from baseline and 12 weeks of treatment with low dose azithromycin or placebo, after stimulation with viral infection mimics (RV16 or Poly (I:C) 12 weeks
Secondary INF-beta gene and/or protein expression To investigate the potential change in viral induced interferon response in HBECs from baseline and after 12 weeks of treatment with low dose azithromycin or placebo, after stimulation with a combination of: viral infection mimics (RV16 or Poly (I:C) +/- allergens (e.g. HDM), +/- scratching of epithelium, +/- smoke exposure. 12 weeks
Secondary IL-33 To investigate the potential change in IL-33 response in HBECs from baseline and after 12 weeks of treatment with low dose azithromycin or placebo, after stimulation with viral infection mimics (RV16 or Poly (I:C) in eosinophilic (blood eosinophils >0.2x109/L) and non-eosinophilic (blood eosinophils <0.2x109/L) patients with asthma and COPD. 12 weeks
Secondary TSLP To investigate the potential change in IL-33 response in HBECs from baseline and after 12 weeks of treatment with low dose azithromycin or placebo, after stimulation with viral infection mimics (RV16 or Poly (I:C) in eosinophilic (blood eosinophils >0.2x109/L) and non-eosinophilic (blood eosinophils <0.2x109/L) patients with asthma and COPD. 12 weeks
Secondary Mast cells, eosinophils, Neutrophils To evaluate the potential change in histologic phenotypes in bronchial biopsies from baseline and after 12 weeks of treatment with low dose azithromycin. 12 weeks
Secondary Lung microbiome To evaluate the potential changes in microbiome abundance in BAL-fluid from baseline and after 12 weeks of treatment with low dose azithromycin measured by 16S gene sequencing. 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device